Johnson and Johnson ( Johnson and Johnson )

Johnson and Johnson

Johnson and Johnson's picture

About Johnson and Johnson

Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Johnson and Johnson press release, blog etc

07/29/2018 - 19:50 Johnson & Johnson Consumer Inc. Announces Agreement to Acquire Zarbees, Inc., a Leader in Naturally-Based Healthcare Products
07/24/2018 - 14:30 Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario
07/24/2018 - 14:22 Janssen announces JULUCA (dolutegravir/rilpivirine) maintains viral suppression with two drugs in a once-daily, single-pill
07/24/2018 - 14:12 Global Partners Pledge over $1.2 billion to Launch the MenStar Coalition
07/24/2018 - 13:31 First Long-term Immune Response Data for Investigational HIV-1 Preventive Vaccine Announced by Johnson & Johnson
07/23/2018 - 15:59 FIRST ISCHEMIC STROKE PATIENTS TREATED WITH EMBOTRAP II REVASCULARIZATION DEVICE SINCE COMMERCIAL AVAILABILITY IN U.S.
07/17/2018 - 12:54 Janssen Announces U.S. FDA Approval of SYMTUZATM (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
07/16/2018 - 14:17 Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
07/13/2018 - 15:57 U.S. FDA Extends Review Timeline for INVOKANA (canagliflozin) Supplemental New Drug Application
07/11/2018 - 17:58 Janssen Provides Update on IMBRUVICA (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
07/05/2018 - 22:57 Johnson & Johnson Announces Publication in The Lancet Highlighting Robust Immune Response to Janssens Mosaic-based Preventive Vaccine Regimen for HIV
06/25/2018 - 21:51 Champions of Science: The Art of Ending Stigma Project Launches to Combat Stigma About Mental Illnesses Through Education and Artistic Creation
06/24/2018 - 00:37 Results further characterize the safety and effectiveness of INVOKANA
06/22/2018 - 23:55 nearly doubled the likelihood of clinically significant weight loss compared to GLP-1s
06/21/2018 - 23:23 Johnson & Johnson Appoints Senior Leaders to Executive Committee
06/21/2018 - 22:46 Johnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. Peterson
06/19/2018 - 07:17 Janssen Phase 3 Study Programme of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Presented for the First Time in Europe
06/14/2018 - 02:01 MERCURY PE is the first prospective, randomized trial to evaluate emergency department discharge in U.S. patients with low-risk PE